Here's the latest...
Advisory committee appointments
IGT Pharma Inc IGT
Shares issued 6,653,332 Aug 26 close $1.03
Tue 26 Aug 97 News Release
Mr Bruce Schmidt reports
Dr Lawrence Mayer, senior research scientist at the BC Cancer Agency and Dr
Kenneth Curry, president of Precision Biochemicals, have been appointed to
IGT's scientific advisory committee.
Dr Mayer brings to IGT over 10 years of experience in preclinical and
clinical testing of new anti-cancer agents. With over five years experience
as a research scientist at the Advanced Therapeutics Department, Medical
Oncology division, BC Cancer Agency and with over 40 published articles and
abstracts to his credit, Dr Mayer, in his advisory capacity with IGT will
be in position to provide guidance to IGT's drug development program.
The BC Cancer Agency cancer centre ranks as one of Canada's most respected
and productive cancer centres, devoted exclusively to cancer patient care,
research, education and prevention.
Dr Kenneth Curry brings to IGT over 10 years of experience in research in
pharmacology/pharmaceutical sciences and medicinal chemistry. An
accomplished researcher with over 50 published articles and abstracts to
his credit, Dr Curry, in his advisory capacity will help to provide
guidance to IGT's drug development program.
Precision Biochemicals is a Vancouver-based manufacturer of specialty
research chemicals. Currently, Precision supplies mostly US distributors
with approximately 300 custom chemicals that are used in both academic
research and pharmaceutical development.
They will join the current advisory board consisting of Dr Radka Milanova,
director of research at IGT, Dr Sewa Legha, professor of medicine at the
M.D. Anderson Cancer Center, University of Texas, and Dr James P. Kutney of
the University of BC and founder of the technology.
IGT recently announced that its new drug, Anhydrovinblastine, has shown
encouraging pre-clinical results in the treatment of tumors associated with
non-small cell lung cancer, the cancer most often associated with smoking.
Application for the commencement of clinical trials is scheduled within the
next six to eight months. |
